Further investigation demonstrated that centrinone B, a selective Plk4 inhibitor, depleted centrioles and induced apoptosis in A375 and Hs294T melanoma cells, suggesting Plk4 is a potential biomarker and drug target in melanoma (11). The gene discussed is PLK4; the disease is melanoma.